Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04759586
Title	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Recruitment	Recruiting
Gender
Phase	Phase III
Variant Requirements	No
Sponsors	National Cancer Institute (NCI)
Indications	primary mediastinal B-cell lymphoma
Therapies	Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate
Age Groups:	child \| adult \| senior
Covered Countries	USA \| CAN \| AUS